

COVAX

CEPI



Supply Chain & Manufacturing Taskforce

May 12, 2021

Where we are today

“Novavax to start shipping COVID-19 vaccines to COVAX program in third quarter”
(Reuters, May 6)

“Moderna commits up to 500M vaccine doses to COVAX”
(Politico, May 3)

“Covax has reserved 500 million doses of the J&J vaccine”
(New York Times, March 12)

Supply and manufacturing challenges remain

“Export controls of input supplies threaten to hinder global vaccine production”
(The Economist, April 24)

“The next big COVID-19 bottleneck? A shortage of trained vaccine workers”
(Fierce Pharma, April 23)

“Syringe shortage hampers Japan's COVID-19 vaccination roll out”
(Reuters, Feb 16)

The Supply Chain & Manufacturing Taskforce has set an impact-ambition along four workstreams

PRELIMINARY

Workstream	Aspiration		Convener
1 Immediate COVAX Response CEPI: N. Lurie & M. Downham	Create partnership to enhance visibility on input supplies Accelerate export permits/custom clearance for critical SKUs Expand fill & finish match making mechanisms	Short-term COVID impact (1-3 months)	
2 Mid-Term COVAX Response CEPI: N. Lurie & M. Downham Gavi: D. Maugeais & H. Kettler	Create overview of global manufacturing capacities Better utilize existing capacities , e.g., voluntary tech transfer Develop regulatory & manufacturing workforce	Mid-term COVID impact (Until end of 2022)	 
3 Long-Term Sustainable Manufacturing WHO: M. Friede & R. Long BMGF: D. Robinson	Expand capabilities of existing manufacturers in LMICs: grow existing capabilities and strengthen the know-how of existing manufacturers Establish sustainable capacity in regions with no significant capacity	Long-term COVID-19 and beyond impact	 
0 Shared fact base / Task Force Coordination Office	Create aligned supply baseline Conduct supply and manufacturing ecosystem mapping Maintain an integrated view of funding requirements across workstreams	Enabling baseline of information	    

Workstream 0: Shared fact base / Task Force Coordination Office

PRELIMINARY

Initial achievements

- Launched **manufacturing taskforce**
- **First draft of ecosystem mapping** (~ 30 organizations, 130 ongoing initiatives)
- **First view of supply data**

Priorities for next weeks

- **Finalize ecosystem mapping** and disseminate further
- Ensure **taskforce is up and running** and whole group convened
- Develop **supply baseline and test assumptions**

Key milestones going forward

- Develop **supply outlook**
(first version end of May)
- Publish aligned **ecosystem mapping**
(first version end of May)
- Create overview of immediate **enabling resources needs**
(end of May)
- Have **Taskforce Coordination Office** up and running (end of May)

Workstream 1: Immediate COVAX Response

PRELIMINARY

Initial achievements

- Validated supplier and manufacturer interest in **input supply marketplace** and detailed marketplace design
 - Identified first set of pain points and solutions for **free flow of goods**
 - Identified key intervention areas for improving **Fill & Finish matchmaking**
 - **Engaged key governments** and stakeholders (e.g., USG, EC)
-

Priorities for next weeks

- **Finalize the charter/terms of participation** to ensure legal compliance and confidentiality
 - **Onboard partners** to marketplace and prepare for launch
 - **Detail list of critical SKUs** and export permit acceleration solutions
 - **Implement intervention** areas identified
-

Key milestones going forward

- **Launch** initial input supply marketplace (*June*)
 - **Launch** free flow of goods interventions (*June*)
 - **Launch** of Fill & Finish matchmaking interventions (*June*)
-

Workstream 2: Mid-Term COVAX Response

PRELIMINARY

Initial achievements

- Identified and accessed key sources of data for existing **capacity mapping**
 - Started framing of key **challenge areas & potential solutions**
 - **Identified interdependencies** with other taskforce workstreams
-

Priorities for next weeks

- Continue **data collection/consolidation** for mapping
 - Finalize assessment and mapping of priority **problems and potential mid-term solutions**
 - **Develop draft solutions** in partnership with manufacturers based on the identified pain points
-

Key milestones going forward

- **Finalize pain points and capacity mapping** and share with key partners (*June*)
 - **Share proposed solutions/COVAX value proposition** to address mid-term capacity challenges with key partners (*June*)
-

Workstream 3: Long-Term Sustainable Manufacturing

PRELIMINARY

Initial achievements

- Initial **EOI** issued by WHO for mRNA hub
 - Aligned on **3 design choices** for expanding & creating vaccine manufacturing in LMICs
 - Defined initial **program structure** (working groups, deliverables, timeline) for detail design and implementation
 - Shared **draft concept note** for input from partners
-


Priorities for next weeks

- Conduct info call on **concept note**, address feedback and confirm optimal go-forward **design model**
 - Complete high-level **costing estimate**
 - Refine **working groups** and identify participants/leads
 - Continue to synthesize **EOI responses & evaluation**
-

Key milestones going forward (see details on following selected WS3 output pages)

- **Design options** developed and evaluated, incl. high-level costing estimate (*end of May*)
 - Target tech & IP landscape initiated, expert panel defined (*end of May*)
 - **Concept note** for design phase released (*end of May*)
 - **Roadmap for next EOIs** completed (*end of May*)
 - **Workstreams launched & detailed planning** of chosen design option conducted (*end of June-end of 2022*)
 - **Plans translated into action** and execution initialized (*2022 and beyond*)
-

WS3 selected output – We defined 3 discrete phases of work for our workstream




WS3 selected output – Vision:
Once design Model is defined, we will embark in a multi-year journey to establish the LMIC network

Release concept note
 Collect EOIs across techs
 (✔ mRNA, viral, protein)



See status on next page

Define criteria, select hub & tech transfer recipients




Design sites, develop business plans



Secure funding



Tech transfer to initial recipients



Expand or build sites for 1-2 recipients



Begin the hub build



Expand hub for additional technologies



Expand recipients to additional technologies



Train recipients and enable Vaccine production



New vaccines in LMICs




● Today ● Rest of 2021 ● 2022 ● Starting in 2023-4

WS3 selected output – Zoom: Currently processing mRNA EOI responses and identifying possible Donors/Recipients

42 responses to date spanning across many regions - preliminary

Including responses from entities based in:



Current activities

- Replied to all respondents to acknowledge submission
- Scheduling calls with promising respondents for additional details
- Reaching out to other entities / countries to complement initial responses
- Defining initial criteria to assess fit with overall network and began donors/recipients assessment

Path forward

- Refine selection of donors/recipients
- Synthesize findings & recommendations
- Prepare for & launch EOIs for other techs in late summer

COVAX

CEPI



Thank you